Ercem Atillasoy

All filings by Ercem Atillasoy on record concern Kalaris Therapeutics, Inc. We count 15 filings; the first trade dates from 29 July 2020 and the latest from 21 October 2022.

Market trades split into 1 purchase (€51k) and 10 sales (€125k). Netting one side against the other leaves €74k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 4 share grants. 2022 to date brings no purchases and 9 sales.

On 26 October 2022 came the latest disclosure, an open-market sale for €13k in Kalaris Therapeutics, Inc. The most recent open-market purchase was published on 5 August 2020, 2,287 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.